Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards® Program

Core Points - Alkermes plc announced the opening of applications for the 7th annual Alkermes Pathways Research Awards program, which will accept applications from September 20, 2024, to November 30, 2024 [1] - The program aims to support early-career researchers focused on advancing understanding of schizophrenia and bipolar disorder, offering grants of up to $100,000 per project [1][4] - Since its inception in 2018, the program has awarded approximately $2.5 million to 25 researchers, leading to multiple journal publications and presentations [5] Program Details - The Alkermes Pathways Research Awards program is designed for early-career investigators who are M.D.s, Ph.D.s, or equivalent, within five years of their initial academic appointment or current post-doctoral fellows affiliated with U.S. medical or research institutions [4] - An independent review committee of specialists in relevant fields will evaluate the applications [4] - The program has been recognized for its impact on supporting researchers, with some recipients obtaining additional funding from the NIH based on their Pathways-funded research [3] Company Overview - Alkermes plc is a global biopharmaceutical company focused on developing innovative medicines in neuroscience, with a portfolio addressing alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder [6] - The company is headquartered in Ireland, with additional offices and facilities in Massachusetts and Ohio [6]